Punctal occlusion often overlooked in management of dry eye disease

Article

Punctal plugs play an important role in the management of dry eye disease, but punctal occlusion is a dramatically underused intervention.

"The treatment recommendations for [DED] issued in 2007 by members of the Management and Therapy Subcommittee of the International Dry Eye WorkShop list punctal plugs as an option for patients with Level 2, moderate-type disease. However, available statistics indicate that only about 12% to 15% of ophthalmologists and optometrists are using this modality," said Dr. Potaznick, associate professor of optometry, Northeastern College of Optometry, Boston.

Needs assessment

Qualifying candidates

Evaluation to identify appropriate candidates should include measurement of tear breakup time, tear meniscus, ocular surface staining with both fluorescein and lissamine green, Schirmer's test or phenol red thread test to assess tear production, and a symptom questionnaire. The latter is also particularly helpful for documenting patient response, Dr. Potaznick noted.

"Improvement in patients with [DED] is a slow and gradual process. It is useful to have some metric to prove to patients they are benefiting from intervention," he explained.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
© 2025 MJH Life Sciences

All rights reserved.